期刊
VACCINE
卷 28, 期 32, 页码 5237-5244出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.05.063
关键词
Recombinant BCG; Tuberculosis; Latency antigen; Vaccine; HspX
资金
- National High Technology Research and Development of China (863 program) [2006AA02Z445]
- Fok Ying Tung Education Foundation [114032]
- National Mega-Projects of Science Research [2008ZX-10003-013]
Immunization with Mycobacterium bovis Bacille Calmette-Guerin (BCG) did not induce adequate Th1 responses to the latency antigen, HspX of M. tuberculosis. To increase the immunogenicity and protective efficacy of BCG, a recombinant BCG strain over-expressing antigen HspX (rBCG::X) was constructed. The recombinant strain rBCG::X expressed high levels of both HspX protein in the cytosol and Ag85B protein in the cytosol and supernatant. Mice vaccinated with rBCG::X produced a more consistent and enduring protective effect against infection with M. tuberculosis, showing lower bacterial load in lung and less severe lung pathology, than the control mice vaccinated with BCG strain containing the vector pMV261. The long-term protection induced by rBCG::X was associated with significant increases in antigen-specific 1FN-gamma to both HspX and Ag85B proteins, while PPD-specific IFN-gamma responses declined. Our results suggest that latency antigens of M. tuberculosis may be promising targets for developing more effective recombinant BCG strains to protect against TB. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据